Coccidioidomycosis / Valley fever

Coccidioidomycosis, commonly known as Valley fever, is a serious fungal infection caused by Coccidioides immitis and Coccidioides posadasii, soil-dwelling fungi endemic to the arid and semi-arid regions of the southwestern United States, Mexico, and parts of Central and South America. This condition develops when cats inhale fungal spores that have become airborne from disturbed soil, particularly during dust storms, construction activities, or digging. While cats are less commonly affected than dogs, feline coccidioidomycosis can be a severe and potentially life-threatening disease that requires prolonged treatment and careful management.

The development of Valley fever in cats begins when microscopic spores called arthroconidia are inhaled into the lungs, where they transform into spherules that multiply and trigger an immune response. In many cats with healthy immune systems, the infection may be contained within the lungs and cause only mild respiratory symptoms or remain subclinical entirely. However, in other cats, particularly those with weakened immune systems, the infection can disseminate through the bloodstream to affect distant sites including bones, joints, skin, lymph nodes, eyes, and the central nervous system. This disseminated form of the disease is much more serious and challenging to treat.

The impact of coccidioidomycosis on feline health ranges from minimal to devastating, depending on the extent of infection and the organs involved. Primary pulmonary infection may cause coughing, difficulty breathing, and general malaise, significantly affecting the cat's quality of life even when confined to the respiratory system. Disseminated disease involving bones and joints causes pain, lameness, and mobility problems. Central nervous system involvement can lead to seizures, behavioral changes, and other neurological deficits. The chronic nature of this infection, which typically requires months to years of treatment, places a significant burden on both affected cats and their caregivers.

Treatment for coccidioidomycosis in cats is possible but requires commitment to long-term antifungal therapy, often lasting six months to several years depending on the extent of infection. Early detection dramatically improves prognosis, as cats treated before dissemination occurs have much better outcomes than those with widespread disease. Veterinary care is essential for diagnosis, which requires specialized testing, and for ongoing monitoring during the extended treatment period. Cat owners in endemic areas should be aware of this disease and seek veterinary attention promptly if their cat develops respiratory symptoms or other signs consistent with Valley fever.

The primary cause of coccidioidomycosis is infection with Coccidioides species fungi, specifically Coccidioides immitis and Coccidioides posadasii. These organisms live in alkaline desert soils and have a complex life cycle involving both environmental and parasitic phases. In the soil, the fungus grows as a mold that produces chains of barrel-shaped spores called arthroconidia. When soil is disturbed by wind, construction, farming, or animal activity, these lightweight spores become airborne and can be inhaled by cats, humans, and other mammals. Once inside the lungs, the arthroconidia transform into spherules, large round structures that produce hundreds of endospores, continuing the parasitic phase of the organism's life cycle.

Genetic and hereditary factors affecting susceptibility to coccidioidomycosis are not well-defined in cats, though individual variation in immune response likely plays a role in determining whether exposure leads to clinical disease. There is no evidence of direct hereditary transmission of susceptibility, but cats with genetic conditions affecting immune function may be more vulnerable to developing severe or disseminated disease. Breed-specific predispositions to coccidioidomycosis have not been established in cats, unlike in dogs where certain breeds appear more susceptible. The primary determinant of infection risk is environmental exposure rather than genetic factors, though individual immune competence influences disease severity.

Environmental factors are the most significant determinants of coccidioidomycosis risk in cats. The disease occurs almost exclusively in endemic regions, with the highest risk areas including southern Arizona, the Central Valley of California, southern New Mexico, west Texas, and parts of Nevada, Utah, and Mexico. Within these areas, risk increases during dry, dusty conditions and following soil disturbance from construction, earthquakes, or dust storms. Outdoor cats have higher exposure risk than indoor cats because they are more likely to encounter contaminated soil. Seasonal patterns exist, with cases often increasing after rainy seasons that promote fungal growth followed by dry periods that facilitate spore dispersal. Climate change may be expanding the endemic range of Coccidioides species.

Risk factors for developing coccidioidomycosis include living in or traveling to endemic areas, outdoor lifestyle with soil contact, and conditions that compromise immune function. Cats with feline immunodeficiency virus, feline leukemia virus, or those receiving immunosuppressive medications face higher risk of severe disease if exposed. Young cats may be more susceptible to disseminated disease, possibly due to immature immune responses. Male cats appear somewhat overrepresented in some case series, though the reason for this is unclear. Cats that actively dig in soil, such as during hunting behavior, may have increased exposure to fungal spores in endemic areas.

The mechanism of disease development begins with inhalation of arthroconidia into the respiratory tract. These spores, measuring only 2-5 micrometers, are small enough to reach the lower airways and alveoli. Once in the lungs, arthroconidia encounter warm, moist conditions that trigger their transformation into spherules. Each spherule matures and produces numerous endospores, which are released when the spherule ruptures, spreading the infection locally within the lungs. The immune system responds with granulomatous inflammation attempting to contain the organisms. In some cats, this response is successful in limiting infection. In others, organisms evade immune containment and enter the bloodstream or lymphatic system, traveling to distant sites where they establish secondary foci of infection. The resulting granulomatous lesions in various organs cause the clinical signs of disseminated coccidioidomycosis.

Early warning signs of coccidioidomycosis in cats are often subtle and easily attributed to other causes, particularly because cats are skilled at concealing illness. Initial symptoms may include mild respiratory signs such as occasional coughing or slightly labored breathing that owners might dismiss as a hairball issue or minor cold. Decreased appetite, weight loss, and reduced energy levels may develop gradually, making them difficult to notice until they become pronounced. Some cats may show no obvious signs during early pulmonary infection, with the disease discovered incidentally during evaluation for other conditions or only becoming apparent after dissemination has occurred. The insidious onset of coccidioidomycosis underscores the importance of regular veterinary care for cats in endemic areas.

Common symptoms of coccidioidomycosis primarily reflect pulmonary involvement in the early stages. Persistent coughing, which may be dry or productive, is frequently observed and may worsen with activity. Labored breathing, rapid respiratory rate, and exercise intolerance indicate significant lung involvement. Fever is common and may fluctuate during the course of illness. Weight loss and poor appetite occur in most symptomatic cats and can be quite dramatic over time. Lethargy and decreased interest in normal activities reflect the systemic effects of chronic infection. Enlarged lymph nodes, particularly those draining the respiratory tract, may be palpable during veterinary examination.

Behavioral changes associated with coccidioidomycosis often reflect the cat's response to feeling unwell. Affected cats frequently become withdrawn, spending more time hiding or sleeping and showing less interest in interaction with family members or other pets. Play behavior decreases, and cats may be reluctant to jump or engage in physical activity. Appetite changes are common, with some cats becoming finicky or refusing food entirely, particularly if the infection causes mouth or throat discomfort. Litter box habits may change if the cat feels too weak to access the box or if urinary or gastrointestinal systems are affected. Irritability or aggression when handled may indicate pain from bone or joint involvement.

Physical signs visible during examination depend on which body systems are affected. Respiratory findings may include increased respiratory rate, labored breathing, and abnormal lung sounds on auscultation. Cats with disseminated disease may show swelling over affected bones, joint enlargement, and pain on palpation of limbs. Skin lesions, including draining tracts, nodules, or non-healing wounds, may develop over dissemination sites. Eye involvement can produce redness, cloudiness, squinting, or visible changes in the eye. Peripheral lymph nodes may be enlarged. Weight loss and muscle wasting become apparent in chronic cases, and the coat may become dull and unkempt as the cat stops grooming normally.

Symptom progression in coccidioidomycosis typically follows a pattern of gradual worsening over weeks to months if untreated. Initial respiratory signs may stabilize, improve, or worsen depending on the cat's immune response and whether the infection remains localized or disseminates. Development of lameness, bone swelling, skin lesions, or neurological signs indicates dissemination and represents significant disease progression. Cats may go through periods of apparent improvement followed by relapse, reflecting the ongoing battle between the organism and immune system. Chronic infection leads to progressive weight loss, debilitation, and eventually organ failure if not treated. The timeline varies considerably between individual cats based on immune status and infection severity.

Emergency symptoms requiring immediate veterinary attention include severe respiratory distress with open-mouth breathing or blue-tinged gums indicating inadequate oxygenation. Acute collapse, seizures, or sudden behavioral changes may indicate central nervous system involvement or septic shock. Sudden severe lameness or inability to walk suggests bone pathology that may include fractures through weakened bone. Complete refusal to eat or drink leading to dehydration constitutes an emergency in any ill cat. High fever unresponsive to supportive care, rapidly enlarging masses, or bleeding from any site warrant urgent evaluation. Cats with known coccidioidomycosis who deteriorate suddenly despite treatment need immediate reassessment.

The initial veterinary examination for suspected coccidioidomycosis involves comprehensive history-taking and physical assessment. The veterinarian will inquire about the cat's geographic history, including current residence, travel to endemic areas, and outdoor access that might result in soil exposure. Duration and progression of symptoms, response to any previous treatments, and presence of known immunocompromising conditions are important historical points. Physical examination focuses on respiratory assessment including auscultation of the lungs, palpation of peripheral lymph nodes, examination of skin for lesions, orthopedic evaluation for bone or joint involvement, and ophthalmologic examination for ocular signs. Fever, weight loss, and body condition are documented.

Diagnostic tests for coccidioidomycosis typically begin with thoracic radiographs to evaluate the lungs, which may show nodular or diffuse interstitial patterns, hilar lymph node enlargement, or pleural effusion. Complete blood count often reveals non-specific changes including mild anemia, elevated white blood cell count with neutrophilia, and sometimes eosinophilia. Serum chemistry assesses overall organ function and may show elevated globulin levels indicating chronic antigenic stimulation. Definitive diagnosis relies on specific testing for Coccidioides, including serology to detect antibodies against the organism and, when possible, identification of the organism in clinical samples through cytology, histopathology, or culture. Cytology or biopsy of accessible lesions may reveal the characteristic spherules diagnostic of coccidioidomycosis.

Serological testing is the most commonly used method for diagnosing coccidioidomycosis in cats. The agar gel immunodiffusion test detects antibodies against Coccidioides antigens and is highly specific when positive. Enzyme-linked immunosorbent assays offer higher sensitivity and can detect infection earlier. However, false-negative results occur, particularly early in infection or in immunocompromised cats who may not mount adequate antibody responses. Serial testing may be needed, with rising antibody titers supporting active infection. Titers can also be used to monitor treatment response, with decreasing levels suggesting successful therapy. Cross-reactivity with other fungi can occasionally cause false positives, so results must be interpreted in clinical context.

Differential diagnosis for coccidioidomycosis includes other fungal infections such as histoplasmosis, blastomycosis, and cryptococcosis, which can produce similar clinical and radiographic findings. Bacterial pneumonia, mycobacterial infections, and parasitic lung disease must also be considered in cats with respiratory signs. Neoplastic conditions, particularly pulmonary lymphoma and metastatic disease, can mimic fungal granulomas on imaging. For cats with bone lesions, differential diagnoses include bacterial osteomyelitis, bone tumors, and other fungal osteomyelitis. Specific diagnostic testing, including fungal culture and histopathologic identification of characteristic spherules, helps distinguish coccidioidomycosis from these other conditions. Geographic history is helpful, as coccidioidomycosis is unlikely in cats with no exposure to endemic regions.

Emergency and immediate treatment for cats with severe coccidioidomycosis focuses on stabilization and supportive care. Cats with respiratory distress may require oxygen supplementation, and those with pleural effusion may need therapeutic thoracocentesis to remove fluid and improve breathing. Intravenous fluid therapy addresses dehydration and supports organ function. Nutritional support, including appetite stimulants or feeding tubes for cats unable to eat voluntarily, prevents further deterioration. Pain management is essential for cats with bone involvement. Antifungal therapy is initiated as soon as the diagnosis is confirmed or strongly suspected, though several days may pass before clinical improvement becomes apparent. Hospitalization may be necessary for critically ill cats until stabilization is achieved.

Medical management of coccidioidomycosis requires prolonged antifungal therapy, typically lasting six months to two years or longer depending on disease severity and treatment response. Fluconazole is often the first-choice antifungal in cats due to its good bioavailability, relatively favorable side effect profile, and ability to penetrate many tissues including bone and the central nervous system. Itraconazole is an alternative that may be preferred in certain situations. Ketoconazole, an older antifungal, is used less commonly due to higher potential for side effects. Amphotericin B, administered intravenously, may be used for severe or refractory cases but requires careful monitoring for kidney toxicity. Treatment continues until clinical resolution and serological improvement, followed by additional months of therapy to prevent relapse.

Surgical options play a limited role in coccidioidomycosis management but may be indicated in specific situations. Drainage of abscesses or debridement of severely affected tissues can reduce organism burden and improve response to medical therapy. In rare cases with localized bone lesions not responding to medication, surgical removal of affected bone segments might be considered. Amputation may be necessary for severe limb involvement that causes uncontrolled pain and does not respond to medical management. Chest tube placement for management of recurrent pleural effusion may be needed in some cats. Surgery is always accompanied by systemic antifungal therapy, as removal of visible disease does not eliminate infection.

Supportive care complements antifungal therapy throughout the treatment period. Nutritional support ensures cats maintain adequate caloric intake, which is challenging when appetite is poor but essential for recovery. High-quality, palatable food should be offered, and warming food may enhance appeal. Pain management using appropriate analgesics improves comfort and quality of life, particularly for cats with bone or joint involvement. Environmental modifications such as low-sided litter boxes, easily accessible food and water, and soft bedding help cats with mobility limitations. Regular monitoring of body weight, appetite, and respiratory status helps track treatment response and identifies complications early.

Alternative and complementary approaches may support conventional treatment but should not replace proven antifungal therapy. Ensuring optimal nutrition and immune support through appropriate diet and supplements may theoretically help the cat's own immune response to the infection. Physical therapy or gentle range-of-motion exercises might benefit cats with joint involvement, though this should be guided by veterinary advice. Stress reduction through environmental enrichment and maintaining routines supports overall wellbeing. Some owners inquire about immune-stimulating supplements, but their efficacy in fungal disease is unproven and should be discussed with the treating veterinarian before use.

Treatment decisions involve balancing disease severity, prognosis, treatment challenges, and financial considerations. The extended duration and cost of antifungal therapy represent significant commitments. Fluconazole, while effective, is not inexpensive when used for many months. Regular monitoring with bloodwork and radiographs adds to the financial burden. Owners must be prepared for a long treatment course with potential setbacks. The prognosis varies with disease extent: cats with localized pulmonary disease have good prospects for recovery, while those with disseminated disease, particularly central nervous system involvement, have more guarded prognoses. Open communication with the veterinary team helps owners make informed decisions about pursuing, continuing, or discontinuing treatment based on realistic expectations and the cat's quality of life.

Recovery timelines for coccidioidomycosis are measured in months to years rather than weeks, reflecting the chronic nature of this infection and the extended treatment required. Cats with localized pulmonary disease may show clinical improvement within two to four weeks of starting antifungal therapy, with resolution of fever, improved appetite, and decreased respiratory signs. However, treatment typically continues for at least six months after clinical resolution and normalization of serological titers. Cats with disseminated disease require even longer treatment, often twelve to eighteen months or more. Some cats with extensive disease may require lifelong antifungal therapy to prevent relapse. The prolonged recovery period demands patience and commitment from both the cat's caregivers and veterinary team.

Post-treatment care focuses on monitoring for relapse, which can occur even after apparently successful treatment. Follow-up appointments are typically scheduled monthly during active treatment, then at increasing intervals after medication is discontinued. Serological monitoring tracks antibody titers, with persistently elevated or rising titers suggesting ongoing infection or relapse. Repeat radiographs assess resolution of pulmonary lesions. Owners should continue monitoring for return of symptoms including coughing, weight loss, lameness, or lethargy, as early detection of relapse allows prompt treatment resumption before significant disease progression. Activity restrictions are usually not necessary during recovery unless specific orthopedic complications require limited mobility.

Prognosis factors in coccidioidomycosis include the extent of disease at diagnosis, presence of dissemination, specific organs involved, the cat's immune status, and response to initial therapy. Cats diagnosed with localized pulmonary disease before dissemination occurs have the best prognosis, with many achieving complete recovery. Disseminated disease carries a more guarded prognosis, though many cats can be successfully managed with extended therapy. Central nervous system involvement is particularly challenging and carries a more guarded prognosis. Immunocompromised cats, including those with FIV or FeLV, have reduced ability to clear infection and may have poorer outcomes. Early response to antifungal therapy is a positive prognostic indicator.

Long-term outlook for cats recovering from coccidioidomycosis depends on successful elimination of infection and prevention of relapse. Cats that complete treatment without relapse can return to normal quality of life without permanent limitations in most cases. Some cats may have residual scarring in the lungs visible on radiographs but without clinical significance. Cats with bone involvement may have some permanent orthopedic changes. Lifelong monitoring is recommended for all cats that have had coccidioidomycosis, as late relapses can occur years after apparently successful treatment. Cats that remain in endemic areas will have ongoing exposure risk, though whether prior infection provides any protection against reinfection is unclear. With appropriate treatment and monitoring, many cats with coccidioidomycosis can enjoy good quality of life for years after diagnosis.

Primary prevention of coccidioidomycosis in cats focuses on reducing exposure to Coccidioides spores in endemic areas. Keeping cats indoors is the most effective preventive measure, as it eliminates contact with contaminated soil. For cats that do go outdoors, avoiding exposure during high-risk periods such as dust storms or windy conditions reduces inhalation of airborne spores. Discouraging digging behavior in outdoor environments limits direct soil contact. If construction or soil disturbance occurs near the home, keeping cats indoors until dust settles reduces exposure risk. There is no vaccine available for coccidioidomycosis prevention in cats, so exposure reduction remains the primary preventive strategy.

Environmental prevention measures within endemic areas include maintaining vegetated ground cover around homes to reduce bare soil exposure, using gravel or paving in areas where cats might have access, and controlling dust through watering or other dust suppression methods when practical. Air conditioning and keeping windows closed during dusty conditions helps protect indoor cats. After windstorms or dust events, allowing time for spores to settle before allowing outdoor access is prudent. Awareness of local coccidioidomycosis incidence through public health reporting helps cat owners understand current risk levels in their area. Avoiding known contaminated sites, if identified, provides additional protection.

Dietary prevention considerations for coccidioidomycosis relate to supporting overall immune function rather than any specific anti-fungal effect. A balanced, complete diet appropriate for the cat's life stage helps maintain immune competence needed to resist infection or contain it if exposure occurs. Adequate protein supports immune cell production, while essential fatty acids, vitamins, and minerals all play roles in immune function. Preventing obesity, which can impair immune responses, is beneficial. Ensuring adequate hydration and addressing any nutritional deficiencies identified through veterinary evaluation supports the cat's natural defenses. No specific dietary supplements have been proven to prevent coccidioidomycosis.

Health maintenance through regular veterinary care supports prevention and early detection of coccidioidomycosis. Routine wellness examinations allow detection of subtle signs that might indicate early infection. Keeping cats up to date on core vaccinations prevents other diseases that could compromise immune function. Testing for and managing conditions such as FIV and FeLV is important since these viruses increase susceptibility to opportunistic infections including coccidioidomycosis. For cats in endemic areas, veterinarians may recommend baseline thoracic radiographs to establish normal appearance, facilitating comparison if respiratory signs develop later. Discussing regional disease risks with veterinary staff helps owners understand what to watch for.

Early intervention strategies for cats in endemic areas focus on prompt recognition and treatment of suspicious symptoms. Owners should be educated about the signs of coccidioidomycosis, including persistent cough, weight loss, lethargy, and lameness, and should seek veterinary attention rather than waiting to see if symptoms resolve. Cats with known immunocompromising conditions warrant heightened vigilance and lower thresholds for diagnostic testing if respiratory or systemic signs develop. Early treatment before dissemination occurs dramatically improves outcomes. Some veterinarians in highly endemic areas may recommend screening serology for high-risk patients or those with compatible symptoms. Maintaining awareness of Valley fever and communicating promptly with veterinary providers gives cats the best chance of early diagnosis and successful treatment.

Daily management of a cat being treated for coccidioidomycosis centers on consistent medication administration and symptom monitoring. Antifungal medications must be given precisely as directed, typically once or twice daily with or without food depending on the specific drug. Missing doses or inconsistent administration can allow the infection to rebound and potentially develop resistance. Owners should establish a routine for medication times that fits their schedule and use pill reminders if needed. Monitoring appetite, energy level, respiratory effort, and any lameness helps track treatment response. Keeping a daily log of observations and medication administration provides valuable information for veterinary follow-ups and helps identify trends that might indicate improvement or deterioration.

Home environment considerations for cats with coccidioidomycosis focus on comfort and accessibility. Cats experiencing respiratory compromise benefit from clean, dust-free environments with good air quality. Those with bone or joint involvement need easy access to food, water, and litter boxes without requiring jumping or climbing. Low-sided litter boxes, elevated food dishes, and soft bedding help maintain comfort. Climate control prevents temperature extremes that could stress an already compromised cat. If the cat was previously an outdoor cat, keeping them indoors during treatment reduces stress, prevents exposure to additional pathogens, and allows closer monitoring. Creating a quiet, comfortable recovery area where the cat can rest undisturbed supports healing.

Maintaining quality of life during the extended treatment period is essential for both the cat's wellbeing and the owner's ability to continue care. Despite illness, most cats can enjoy gentle interaction, comfortable resting spots, and mental stimulation appropriate to their energy level. Offering favorite foods within any dietary restrictions, providing window perches for bird watching, and spending quiet time together preserves the human-animal bond. Pain management ensures cats with bone involvement remain comfortable. Recognizing that recovery takes time and celebrating small improvements helps maintain a positive outlook. If quality of life deteriorates significantly despite treatment, honest conversations with the veterinary team about expectations and options are appropriate.

Monitoring and ongoing veterinary care are essential throughout treatment and beyond. Regular recheck appointments allow assessment of clinical response, adjustment of therapy if needed, and monitoring for drug side effects. Periodic bloodwork checks liver and kidney function, which can be affected by antifungal medications. Serial radiographs track resolution of pulmonary lesions. Serological testing monitors antibody levels, with declining titers suggesting successful treatment. Owners should know which warning signs require immediate veterinary contact, including respiratory distress, acute lameness, seizures, or sudden deterioration. After treatment completion, ongoing surveillance for relapse continues indefinitely through periodic veterinary visits and owner observation.

Caregiver support resources are valuable given the emotional and financial challenges of managing coccidioidomycosis. The extended treatment duration, uncertain outcomes, and significant costs can cause caregiver stress and fatigue. Connecting with other pet owners who have experienced similar situations through online forums or support groups provides emotional support and practical advice. Open communication with the veterinary team about financial constraints, emotional concerns, and quality of life questions helps ensure management plans remain sustainable and aligned with the owner's values. Some veterinary schools, non-profit organizations, or pharmaceutical manufacturers offer financial assistance programs for extended treatments. Self-care for caregivers, including maintaining their own health and seeking support when needed, enables them to provide the best care for their cats throughout the long treatment journey.

No specific cat breeds have been identified as having genetic predisposition to coccidioidomycosis, as this is an environmentally acquired infection depending on geographic exposure rather than hereditary factors. All cat breeds living in or traveling to endemic areas face similar risk of exposure to Coccidioides spores. The likelihood of developing clinical disease after exposure depends more on individual immune function than on breed-related factors. Outdoor cats of any breed face higher exposure risk than strictly indoor cats due to their contact with potentially contaminated soil. Young cats may be somewhat overrepresented in clinical cases, possibly due to outdoor exploration behavior or developing immune systems.

Rather than breed-specific risk, individual risk factors determine which cats are most likely to develop severe or disseminated disease following exposure. Cats with concurrent immunosuppressive conditions, regardless of breed, face the greatest risk. This includes cats infected with feline immunodeficiency virus or feline leukemia virus, those receiving immunosuppressive medications for other conditions, and cats with chronic illnesses that may impair immune function. Senior cats may have some degree of immune senescence that could affect their response to infection. Theoretically, breeds predisposed to conditions affecting immune function might have indirect increased risk, but no specific breed associations with coccidioidomycosis have been established in veterinary literature.

Screening recommendations for coccidioidomycosis relate to geographic risk and clinical suspicion rather than breed. Cats living in endemic areas, particularly outdoor cats, should have veterinary evaluation if they develop persistent respiratory signs, unexplained weight loss, or other compatible symptoms. Baseline serological testing is not routinely recommended for healthy cats but may be considered for cats with high exposure risk or those being evaluated for compatible clinical signs. Cats with known immunocompromising conditions living in endemic areas warrant heightened awareness and potentially lower thresholds for diagnostic testing. There are no breed-specific health screening panels that include coccidioidomycosis testing. The best prevention remains limiting exposure through indoor housing for cats in endemic regions.

Several conditions commonly co-occur with or predispose to coccidioidomycosis in cats. Feline immunodeficiency virus infection significantly increases susceptibility to opportunistic infections including fungal diseases, and cats with both conditions face more challenging treatment and guarded prognosis. Feline leukemia virus similarly compromises immune function and may be found concurrently with coccidioidomycosis. Diabetes mellitus, which impairs immune responses, may predispose cats to more severe fungal infections. Cats receiving immunosuppressive therapy for conditions such as inflammatory bowel disease or immune-mediated diseases have increased susceptibility to opportunistic infections. Management of coccidioidomycosis in cats with concurrent conditions requires addressing all health issues while being mindful of potential drug interactions and cumulative organ effects.

Conditions with similar symptoms to coccidioidomycosis include other systemic fungal infections endemic to overlapping geographic regions. Histoplasmosis, caused by Histoplasma capsulatum, produces similar pulmonary and disseminated disease patterns and is found in the central United States overlapping with some coccidioidomycosis endemic areas. Blastomycosis, predominantly in midwestern and southeastern states, also causes respiratory and disseminated disease. Cryptococcosis, distributed more widely, can affect the respiratory tract, central nervous system, and other sites similarly to disseminated coccidioidomycosis. Distinguishing between these fungal infections requires specific diagnostic testing, as treatment approaches and prognosis differ. Non-fungal conditions including pulmonary neoplasia, bacterial pneumonia, and mycobacterial infections may also present similarly.

Potential complications of coccidioidomycosis include secondary bacterial infections in damaged lung tissue or draining skin lesions, requiring concurrent antibiotic therapy. Pathological fractures can occur through bone weakened by granulomatous osteomyelitis, causing acute pain and mobility loss. Central nervous system involvement, including meningitis, carries significant morbidity and mortality risk. Ocular complications such as uveitis, retinal detachment, or endophthalmitis can result in vision loss. Chronic wasting from prolonged illness and poor appetite leads to muscle loss and weakness. Medication side effects, particularly hepatotoxicity from long-term azole antifungal therapy, represent iatrogenic complications requiring monitoring. Relapse after apparently successful treatment is a common complication that may occur months to years after therapy discontinuation, necessitating ongoing vigilance.